How do GLP-1 agonists compare against other strategies for weight reduction and cancer risk reduction? Elizabeth Tracey reports

Podcast: Download (Duration: 1:03 — 1.5MB)

Subscribe: RSS

For some types of cancer obesity is clearly a risk factor. Now a new study shows that when people with obesity take a GLP-1 agonist to lose weight, they also reduce their risk for these cancers. Kimmel Cancer Center director William Nelson at Johns Hopkins looks at the specific findings.

Nelson: They looked at those who use the GLP one receptor agonists and fulfilled at least two prescriptions to compare against people who were formally recommended to undergo diet and exercise. What they found was a 41% reduction overall in the risk for cancer. One that was compelling was multiple myeloma, endometrial cancer that’s cancer of the uterus, colorectal cancer and thyroid cancer. More and more evidence hinting that if you can treat obesity effectively may reduce the risk of cancers that seem to be increased.  :32

Nelson notes that this is just one more reason to lose weight, adding to the multiple health benefits that accrue. At Johns Hopkins, I’m Elizabeth Tracey.